Opus Point Partners Management’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Opus Point Partners Management’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-58,000	Closed	-$5.52M	–	50
2018 Q2	$5.52M	Buy	58,000 +34,200	+144%	+$3.14M	11.97%	1
2018 Q1	$2.09M	Sell	23,800 -41,200	-63%	-$3.76M	4.1%	4
2017 Q4	$5.52M	Hold	65,000	–	–	4.77%	3
2017 Q3	$5.63M	Hold	65,000	–	–	5.05%	3
2017 Q2	$5.02M	Sell	65,000 -65,000	-50%	-$4.61M	4.6%	3
2017 Q1	$9.01M	Hold	130,000	–	–	6.69%	1
2016 Q4	$7.7M	Hold	130,000	–	–	6.13%	2
2016 Q3	$8.62M	Buy	130,000 +71,143	+121%	+$4.4M	4.83%	3
2016 Q2	$3.18M	Buy	+58,857	New	+$3.22M	3.07%	8
2015 Q1	–	Sell	-62,400	Closed	-$3.88M	–	70
2014 Q4	$3.88M	Buy	+62,400	New	+$3.56M	3.84%	4

Other funds holding XBI

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Rafferty Asset Management New York $43.9B AUM 121.74% 1-Year Est. Return

Opus Point Partners Management's XBI Position: Q3 2018 in Review

Opus Point Partners Management sold out of State Street SPDR S&P Biotech ETF (XBI) in Q3 2018, closing a stake of 58,000 shares — an estimated $5.52M sold.

Opus Point Partners Management first reported a position in XBI in Q4 2014 and held it in 10 quarters. The position peaked at $9.01M in Q1 2017. 432 funds tracked by Wall St. Rank hold XBI as of Q3 2018.

Opus Point Partners Management reported no remaining State Street SPDR S&P Biotech ETF position as of Q3 2018 after selling out during the quarter.
Opus Point Partners Management sold 58,000 State Street SPDR S&P Biotech ETF shares in Q3 2018, an estimated $5.52M.
Opus Point Partners Management first reported a position in State Street SPDR S&P Biotech ETF in Q4 2014 and held it in 10 quarters.
Opus Point Partners Management's State Street SPDR S&P Biotech ETF position peaked at $9.01M in Q1 2017.
432 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q3 2018.

Based on Opus Point Partners Management's 13F filing for Q3 2018, filed 14 Nov 2018.